Publications & Scientific Output
My scientific work spans translational oncology, pancreatic cancer biology, tumor microenvironment biology, chromatin and epigenetic regulation, NSCLC biology, thyroid cancer, and preclinical cancer models.
Peer Reviewed Publications
RANBP9 and RANBP10 cooperate in regulating non-small cell lung cancer proliferation
Orlacchio A, Kajimura Y, Rizzotto L, Tessari A, Soliman SHA, Visone R, Zhang L, Fries B, Tessarollo L, Amann J, Carbone DP, Lodi A, Ahmed A, Gorgoglione R, Fiermonte G, Freitas M, Palmieri D, Kaufman J, Coppola V
Journal of Experimental & Clinical Cancer Research. 2025;44(1):259.
Focus: NSCLC biology, CTLH complex, tumor proliferation, preclinical oncology.
DOI: 10.1186/s13046-025-03491-8 | PMID: 40883813
Continuous Regression of Metastatic Pancreatic Adenocarcinoma after Suspending Chemotherapy: A Case Report
Bayat L, Orlacchio A, Parrott D, Wu J
Case Reports in Oncology. 2025;18(1):1552–1561.
Focus: Pancreatic cancer, exceptional clinical response, translational molecular interpretation.
DOI: 10.1159/000549360 | PMID: 41323041
Epigenetic therapeutic strategies in pancreatic cancer
Orlacchio A, Muzyka S, Gonda TA
International Review of Cell and Molecular Biology. 2024;383:1–40.
Focus: Pancreatic cancer, epigenetic therapy, chromatin regulation, translational oncology.
DOI: 10.1016/bs.ircmb.2023.10.002 | PMID: 38359967
The Role of Toll-like Receptors (TLRs) Mediated Inflammation in Pancreatic Cancer Pathophysiology
Orlacchio A, Mazzone P
International Journal of Molecular Sciences. 2021;22(23):12743.
Focus: Pancreatic cancer, inflammation, innate immunity, tumor microenvironment.
DOI: 10.3390/ijms222312743 | PMID: 34884547
SGK1 is a critical component of an AKT-independent pathway essential for PI3K-mediated tumor development and maintenance
Orlacchio A, Ranieri M, Brave M, Antico Arciuch V, Forde T, De Martino D, Anderson KE, Hawkins PT, Di Cristofano A
Cancer Research. 2017.
Focus: PI3K signaling, SGK1, thyroid cancer, target discovery, genetically engineered models.
DOI: 10.1158/0008-5472.CAN-17-2105 | PMID: 29055016
PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer
De Martino D, Yilmaz E, Orlacchio A, Ranieri M, Zhao K, Di Cristofano A
Cancer Letters. 2018;439:56–65.
Focus: Anaplastic thyroid cancer, drug combination strategy, PI3K pathway, PLK1 inhibition.
PMID: 30243708
An in vivo “turning model” reveals new RanBP9 interactions in lung macrophages
Kajimura Y, Dong S, Tessari A, Orlacchio A, Thoms A, Cufaro MC, Di Marco F, Amari F, Chen M, Soliman SHA, Rizzotto L, Zhang L, Sunilkumar D, Amann JM, Carbone DP, Ahmed A, Fiermonte G, Freitas MA, Lodi A, Del Boccio P, Tessarollo L, Palmieri D, Coppola V
Cell Death Discovery. 2025;11(1):171.
Focus: RanBP9 biology, lung macrophages, in vivo model development, proteomics.
DOI: 10.1038/s41420-025-02456-2 | PMID: 40223093
Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought
Agostini A, Orlacchio A, Carbone C, Guerriero I
Frontiers in Immunology. 2022;13:876291.
Focus: PDAC tumor microenvironment, immune suppression, stromal biology, therapeutic resistance.
DOI: 10.3389/fimmu.2022.876291 | PMID: 35711414
Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis
Soliman SHA, Orlacchio A, Verginelli F
Microorganisms. 2021;9(6):1179.
Focus: Viral oncogenesis, epigenetic regulation, cancer biology.
DOI: 10.3390/microorganisms9061179 | PMID: 34070716
Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy
Guerriero I, Monaco G, Coppola V, Orlacchio A
Pharmaceuticals. 2020;13(11):413.
Focus: SGK1 biology, NSCLC therapy, signaling pathways, therapeutic targeting.
DOI: 10.3390/ph13110413 | PMID: 33266470
Tagging enhances histochemical and biochemical detection of Ran Binding Protein 9 in vivo and reveals its interaction with Nucleolin
Soliman SHA, Stark AE, Gardner ML, Harshman SW, Breece CC, Amari F, Orlacchio A, Chen M, Tessari A, Martin JA, Visone R, Freitas MA, La Perle KMD, Palmieri D, Coppola V
Scientific Reports. 2020;10:7138.
Focus: RanBP9 biology, genetically engineered mouse models, protein detection, in vivo validation.
DOI: 10.1038/s41598-020-64047-8 | PMID: 32346083
RANBP9 as potential therapeutic target in non-small cell lung cancer
Tessari A, Soliman SHA, Orlacchio A, et al.
Journal of Cancer Metastasis and Treatment. 2020;6:18.
Focus: NSCLC, RANBP9, therapeutic target discovery, platinum response.
DOI: 10.1016/j.canlet.2018.09.024 | PMID: 34778565
Genetic ablation of interacting with Spt6 (Iws1) causes early embryonic lethality
Orlacchio A, Stark AE, Foray C, Amari F, Sheetz T, Reese E, Tessari A, La Perle KMD, Palmieri D, Tsichlis PN
PLOS ONE. 2018;13(9):e0201030.
Focus: IWS1 biology, mouse genetics, embryonic development, gene function.
DOI: 10.1371/journal.pone.0201030 | PMID: 30208029
Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis
Champa D, Orlacchio A, Patel B, Ranieri M, Shemetov AA, Verkhusha VV, Cuervo AM, Di Cristofano A
Oncotarget. 2016;7(23):34453–34471.
Focus: Anaplastic thyroid cancer, lysosomal vulnerability, necrotic cell death, preclinical therapy.
DOI: 10.18632/oncotarget.9121 | PMID: 27144341
MCM5 as a Target of BET Inhibitors in Thyroid Cancer Cells
Mio C, Lavarone E, Conzatti K, Baldan F, Toffoletto B, Puppin C, Filetti S, Durante C, Russo D, Orlacchio A, Di Cristofano A, Di Loreto C, Damante G
Endocrine-Related Cancer. 2016;23(4):335–347.
Focus: Thyroid cancer, BET inhibition, MCM5, epigenetic therapeutic targeting.
DOI: 10.1530/ERC-15-0322 | PMID: 26911376
Conference Proceedings — Posters & Presentations
Dual-function platform for chemotherapy prediction and mutation detection in pancreatic cancer by tCAM-seq.
Orlacchio A, Ladewig E, Chandra AK, Dhara A, James SM, Leach SD, Yu KH, Dhara S
AACR Annual Meeting 2026 (Abstract 2451)
Predictors of inadequate ovarian function suppression (OFS) in premenopausal women with hormone receptor (HR)-positive breast cancer receiving a gonadotropin-releasing hormone (GnRH) agonist in combination with endocrine therapy
Kwa M, Bayat L, Chan N, Orlacchio A, Karayigitoglu C, Ayoubi D, Hochman T, Marks D
SABCS 2024 (Abstract P2-08-09)
Low-dose dual epigenetic therapy utilizing hypomethylating agents and HDAC inhibitors prolongs survival in an orthotopic PDAC model and alters the tumor microenvironment.
Muzyka S, Orlacchio A, Ackermann A, Chinda Y, Shim Y, Dolgalev I, Gonda T
AACR Special Conference: Advances in Pancreatic Cancer Research 2024 (Abstract B062)
Low-dose double epigenetic therapy improves immunotherapy response and prolongs survival in pancreatic cancer.
Orlacchio A, Muzyka S, Li J, Simeone DM, Gonda T
Digestive Disease Week (DDW) 2024 (Gastroenterology)
Dual epigenetic therapy combined with anti-PD1 rescues HMA-induced suppressive myeloid phenotype and reduces tumor growth in a PDAC model.
Orlacchio A, Muzyka S, Do C, Simeone DM, Gonda T
AACR Special Conference: Advances in Pancreatic Cancer Research 2023 (Abstract B043)
Hypomethylating therapy induces a potential immuno-suppressive myeloid phenotype by altering cancer cell cytokine secretion in PDAC.
Orlacchio A, Weissinger D, Do C, Tycko B, Simeone DM, Gonda T
AACR Special Conference: Advances in Pancreatic Cancer Research 2022 (Abstract C041)
RANBP9 presence affects levels of Tip60 and activated p53 in lung cancer cells in response to DNA damage.
Soliman S, Orlacchio A, Tessari A, Capece M, Visone R, Croce C, Palmieri D, Coppola V
AACR Annual Meeting 2019 (Abstract 3514)
Genetic ablation of interacting with Spt6 (Iws1) causes early embryonic lethality.
Orlacchio A, Stark AE, Foray C, Amari F, Sheetz T, Reese E, Tessari A, La Perle K, Palmieri D, Tsichlis PN, Coppola V
AACR Annual Meeting 2018 (Abstract 359)
SGK1 activation is essential for PI3K-dependent tumor development.
Orlacchio A, Di Cristofano A.
AACR Annual Meeting 2017 (Abstract 330).
Driver pathway blockage synergizes with PLK1 inhibition in anaplastic thyroid cancer.
De Martino D, Yilmaz E, Orlacchio A, Di Cristofano A.
AACR Annual Meeting 2017 (Abstract 1068).
Combination of PLK1 and PI3K inhibitors shows strong synergy
in anaplastic thyroid cancer.
Yilmaz E, Orlacchio A, Di Cristofano A.
AACR Annual Meeting 2016 (Abstract 2713).
Beyond AKT: Critical pathways for PI3K-dependent transformation.
Orlacchio A, Di Cristofano A.
AACR Annual Meeting 2016 (Abstract 4376).
PDK1-dependent activation of RSK is an absolute requirement for PI3K oncogenic activity in the thyroid gland.
Orlacchio A, Di Cristofano A.
AACR Annual Meeting 2015 (Abstract 2158).
MYC amplification and overexpression in metastatic anaplastic thyroid cancer dictates response to therapy.
Yilmaz E, Russo MA, Orlacchio A, Forde T, Di Cristofano A.
AACR Annual Meeting 2015 (Abstract 2023).
PDK1-dependent activation of AGC kinases is an absolute requirement for AKT oncogenic activity.
Orlacchio A, Antico Arciuch V, Di Cristofano A.
AACR Annual Meeting 2014 (Abstract 4776).